| Phase II study of axitinib in sorafenib-refractory metastatic ... - UroToday |
|
|
UroToday... 2, and 3 in patients with metastatic renal cell carcinoma (mRCC) refractory to prior therapies that included, but were not limited to, sorafenib. ... read more |